Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effects of Ziltivekimab Versus Placebo on Heart Failure Symptoms and Physical Function in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction and Systemic Inflammation

Next Previous
Trial Profile

Effects of Ziltivekimab Versus Placebo on Heart Failure Symptoms and Physical Function in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction and Systemic Inflammation

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 07 Sep 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ziltivekimab (Primary)
  • Indications Heart failure; Inflammation
  • Focus Registrational; Therapeutic Use
  • Acronyms ATHENA
  • Sponsors Novo Nordisk

Most Recent Events

  • 09 Jun 2026 Status changed from recruiting to active, no longer recruiting.
  • 11 Mar 2026 Planned End Date changed from 10 Jan 2027 to 8 Jan 2027.
  • 11 Mar 2026 Planned primary completion date changed from 5 Oct 2026 to 1 Oct 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top